Skip to main content
. 2015 Jan 2;9(2):1461–1470. doi: 10.1021/nn505895j

Table 1. Cell Viability Data for Compound 8·2Cl and Doxorubicin for the 10 Cell Lines Tested.

  cell viability (%)
cell line 2Cl doxorubicin
FaDu 20.6 ± 1.1 72.2 ± 0.9
SKMEL-2 7.2 ± 2.5 6.9 ± 7.3
HT-29 14.9 ± 1.7 54.3 ± 0.9
HT-1080 35.6 ± 1.8 56.3 ± 5.5
HepG2 66.8 ± 5.2 74.9 ± 1.0
HL-60 51.1 ± 3.4 4.0 ± 2.5
Jurkat 28.9 ± 1.9 6.7 ± 0.9
PC-3 45.6 ± 1.2 59.7 ± 1.1
HeLa 32.3 ± 1.8 3.9 ± 4.0
MDA-MB-231 66.1 ± 3.5 61.1 ± 1.3